Skip to content



President Trump received mostly the same treatment as anyone would get for COVID-19, except for one experimental drug and the speed of his care.


The claim: Antibody cocktail Trump received is made from fetal stem cells 

Since President Donald Trump’s COVID-19 diagnosis and hospitalization, health care professionals have voiced concerns regarding his broad medical regimen, which include steroid dexamethasone and Gilead’s remdesivir. One treatment in particular, an experimental antibody drug from Regeneron Pharmaceuticals, is drawing criticism on social media. 

“So it turns out the monoclonal antibodies Trump is on are from fetal stem cells. So Trump is being treated/saved with dead babies,” reads a Twitter post shared on the Facebook group Dogs for Democracy.

The tweet goes on to call out Republicans,  Supreme Court nominee Judge Amy Coney Barrett and anti-abortion activists.  

Fact or fiction: We’re fact checking the news and sending it to your inbox. Sign

Read More

The India Cellular & Electronics Association (ICEA) has urged the Finance Ministry to extend the zero duty on open cell for televisions beyond September, for another three years to boost domestic manufacturing and curb imports of LED TVs under FTAs.

In its letter to the Finance Ministry, the industry body said currently there are no manufacturers for open cell and that it will take 3-4 years for a company to establish a plant. “If the duty on open cell is not extended beyond September 2020, it will again lead to high imports of LED TVs under FTA, a huge blow to the ‘Make in India’ programme of government. It will have an adverse impact on the domestic television manufacturers,” it stated. It has instead recommended the implementation of the proposed phased manufacturing plan for TVs where duty on open cells can be levied post the fab becomes operational. Open cell

Read More

DUBLIN–(Business Wire)–The “Primary Cells – Global Market Trajectory & Analytics” report has been added to’s offering.

The publisher brings years of research experience to the 5th edition of this report. The 175-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Primary Cells Market to Reach US$1.3 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Primary Cells estimated at US$775.5 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2027, growing at a CAGR of 7.1% over the period 2020-2027.

Human Primary Cells, one of the segments analyzed in the report, is projected to grow at a 7.5% CAGR to reach US$1 Billion by the end of the analysis period. After an early analysis of the

Read More

Researchers at Karolinska Institutet in Sweden have identified a small neutralizing antibody, ‘nanobody’ of sorts that can block the novel coronavirus from entering human cells.

The nanobodies have the capacity to block SARS-CoV-2, the virus that has caused the COvid-19 pandemic, from entering human cells. The results of the study have been published in the journal Nature Communications.

The nanobodies occur naturally in camelids and can be adapted for humans. Researchers injected an alpaca with the coronavirus spike protein to identify the small antibodies.

The tests results

The blood samples of the alpaca showed a strong immune response against the virus within sixty days. Researchers then studied the animal’s blood samples to identify and isolate the nanobody that can prevent infection. They identified a small antibody called ‘Ty1’, named after the alpaca Tyson, that “efficiently neutralizes the virus by attaching itself to the part of the spike protein that binds

Read More

Designed using Magazine News Byte. Powered by WordPress.